The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.
D000970:Antineoplastic Agents / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D003470:Culture Media; D013196:Dihydrotestosterone / Q000494:pharmacology; D005204:Farnesol / Q000031:analogs & derivatives* / Q000633:toxicity*; D006801:Humans; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D012459:Salicylates / Q000633:toxicity*
D000970:Antineoplastic Agents; D003470:Culture Media; D012459:Salicylates; C093323:farnesylthiosalicylic acid; D013196:Dihydrotestosterone; D005204:Farnesol; D019869:Phosphatidylinositol 3-Kinases; D020928:Mitogen-Activated Protein Kinases